SURGE: Supporting Utility and Representation in Genomics-based Cancer Trial Enrollment (Intervention)

Last updated: September 14, 2026
Sponsor: Nadine Jackson, MD, MPH
Overall Status: Active - Recruiting

Phase

N/A

Condition

Stomach Cancer

Digestive System Neoplasms

Hematologic Cancer

Treatment

SURGE

Clinical Study ID

NCT05375643
21-709
  • Ages > 18
  • All Genders

Study Summary

SURGE aims to increase representation in clinical trial enrollment by addressing barriers to genomic testing, which is increasingly needed to assess precision clinical trial eligibility and access standard precision therapies. The study is an interventional pilot meant primarily to assess the feasibility of the intervention. The intervention is comprised of a patient navigator, text message questionnaire, and informational video.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Adult (age 18 years or older)

  • Scheduled for a new patient consultation

  • Suspected or confirmed advanced malignancy (requiring active treatment)

  • DFCI patient at Longwood/Chestnut Hill, DFCI satellite at BMC-Brighton (formerly St.Elizabeth's Medical Center), DFCI satellite at Foxborough, or DFCI satellite atMerrimack Valley

Exclusion

Exclusion Criteria:

  • Malignancy or former malignancy that requires only surveillance

  • Not continuing care at a participating DFCI site

  • Speaks a language other than English, Spanish, Haitian Creole, Russian, Portuguese,Arabic, or Traditional Chinese

  • Unable to provide consent

Study Design

Total Participants: 210
Treatment Group(s): 1
Primary Treatment: SURGE
Phase:
Study Start date:
April 03, 2023
Estimated Completion Date:
July 30, 2028

Study Description

Supporting Utility and Representation in Genomics-based cancer trial Enrollment (SURGE) is a multimodal intervention to address medical literacy and unmet social determinants of health (SDoH) needs as barriers to tumor somatic genomic testing consent among historically underrepresented patients (HUP) diagnosed with advanced solid or hematologic malignancies as a prerequisite to precision therapies and/or clinical trial eligibility. Our key hypothesis is that video-based education with or without 1:1 patient navigation will address medical literacy and unmet SDoH barriers, supporting HUP decision-making about genomic tumor consent. We will conduct a type 1 hybrid implementation effectiveness study among a cohort of HUP seeking medical oncology care at two academic and two community practice sites.

Connect with a study center

  • Dana Farber Cancer Institute

    Boston, Massachusetts 02215
    United States

    Active - Recruiting

  • Dana-Farber Cancer Institute at St. Elizabeth's Medical Center

    Brighton, Massachusetts 02135
    United States

    Active - Recruiting

  • Dana-Farber Cancer Instiute - Merrimack Valley

    Methuen, Massachusetts 01844
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.